April 8, 2008 — Allon Therapeutics Inc. (TSX: NPC), presented at the BIO-Europe Spring 2008 partnership conference in Madrid, Spain sharing with prospective pharmaceutical partners the human efficacy data from the Company’s Phase IIa clinical trial in patients with amnestic mild cognitive impairment (aMCI), a precursor to Alzheimer’s disease (AD). Allon announced February 26, 2008 initial top-line data showing that the Company’s drug AL-108 had a positive impact on memory function in patients with aMCI. Statistically significant, dose dependent and durable improvement was measured in two key cognitive tests, delayed-match-to-sample (DMTS) and digit span, which are widely recognized and validated as effective measures of memory function relevant to Alzheimer’s disease... Allon's Press Release -
